Probi initiates partnership with Clasado for the development of synbiotics
Probi has entered into a partnership with Clasado Biosciences ("Clasado"), a company renowned for its research and development of prebiotics and the multi-award-winning ingredient Bimuno® GOS.
Clasado is a company renowned for its research in prebiotics, and their prebiotic product Bimuno® GOS holds a leading market position and is one of the most clinically studied prebiotic ingredients with over 20 clinical trials. The purpose of this partnership is to leverage Probi's and Clasado's market-leading and scientific portfolios in probiotics and prebiotics, respectively, to develop health-promoting synbiotic products.
Synbiotics are the combination of prebiotics and probiotics that can interact and enhance each other's effects on the gut microbiome and health. Synbiotics can be used for their complimentary benefits or aim to be synergistic and improve the survival and colonization of beneficial bacteria in the gut, which can provide benefits for gut health, digestion, and immune function. Awareness of good digestive health is rapidly increasing, driving the demand for complementary products. According to the analysis firm Mordor Intelligence, the market for synbiotic products is growing strongly and is expected to grow globally by over eight percent per year over the next five years.
"Collaborating with Clasado is a fantastic opportunity. Through this partnership, we aim to explore the potential of combining our probiotic strains with Bimuno® GOS and lay the foundation for exciting synbiotic collaborations," says Anita Johansen, CEO of Probi.
"We are thrilled to partner with Probi, combining our expertise to develop synbiotic products for priority health areas. This science-driven collaboration will benefit consumers worldwide," says Per Rehné, CEO of Clasado.
Initially, the collaboration will focus on advancing the collective understanding of prebiotic and probiotic combinations, but it also opens up future opportunities for the companies in terms of research, development, and commercialization of a joint synbiotic technology.
Difference between probiotics, prebiotics, and synbiotics:
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
A prebiotic is a substrate that is selectively utilized by host microorganisms conferring a health benefit.
Synbiotics are mixtures, comprising live microorganisms and substrate(s) selectively utilized by host microorganisms, that confers a health benefit on the host. Synbiotics may be formulated using either a complementary or synergistic approach.
For further information, please contact:
Anita Johansen, CEO, Probi, Phone: +46 46 286 89 48, E-mail: [email protected]
ABOUT PROBI
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.
